Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL.
Soumerai JD, Barrientos JC, Ahn IE, Coombs CC, Gladstone DE, Hoffmann MS, Kittai AS, Jacobs RW, Lipsky A, Patel K, Rhodes JM, Skarbnik AP, Thompson MC, Ermann DA, Reville PK, Shah HR, Brown JR, Stephens DM. Soumerai JD, et al. Among authors: ahn ie. Blood Adv. 2024 Nov 19:bloodadvances.2024014474. doi: 10.1182/bloodadvances.2024014474. Online ahead of print. Blood Adv. 2024. PMID: 39561376
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
Ahn IE, Brander DM, Ren Y, Zhou Y, Tyekucheva S, Walker HA, Black R, Montegaard J, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng SY, Crombie J, Fisher DC, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Brown JR, Davids MS. Ahn IE, et al. Blood Adv. 2024 Feb 27;8(4):832-841. doi: 10.1182/bloodadvances.2023011574. Blood Adv. 2024. PMID: 38163317 Free PMC article. Clinical Trial.
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.
Merryman RW, Michaud L, Redd R, Mondello P, Park H, Spilberg G, Robertson M, Taranto E, Ahmed G, Chase M, Jeter E, Ahn IE, Brown JR, Crombie J, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Salles G, Zelenetz AD, Armand P, Schöder H, Jacene H. Merryman RW, et al. Among authors: ahn ie. Hemasphere. 2023 Jan 24;7(2):e826. doi: 10.1097/HS9.0000000000000826. eCollection 2023 Feb. Hemasphere. 2023. PMID: 36713355 Free PMC article.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
Merryman RW, Redd RA, Freedman AS, Ahn IE, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen ED, Kim AI, LaCasce AS, Ng S, Odejide OO, Parry EM, Isufi I, Kline J, Cohen JB, Mehta-Shah N, Bartlett NL, Mei M, Kuntz TM, Wolff J, Rodig SJ, Armand P, Jacobson CA. Merryman RW, et al. Among authors: ahn ie. Ann Hematol. 2024 Jan;103(1):185-198. doi: 10.1007/s00277-023-05475-0. Epub 2023 Oct 18. Ann Hematol. 2024. PMID: 37851072 Clinical Trial.
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
Baskar S, Peng H, Gaglione EM, Carstens EJ, Lindorfer MA, Ahn IE, Herman SEM, Skarzynski M, Chang J, Keyvanfar K, Butera V, Blackburn AZ, Vire B, Maric I, Stetler-Stevenson M, Yuan CM, Eckhaus MA, Soto S, Farooqui MZH, Taylor RP, Rader C, Wiestner A. Baskar S, et al. Among authors: ahn ie. Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846. Online ahead of print. Blood. 2025. PMID: 39774793
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Lo S, Olszewski AJ, Arnason JE, Ahn IE, Brown JR. Davids MS, et al. Among authors: ahn ie. J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503. Online ahead of print. J Clin Oncol. 2024. PMID: 39645236
Prognostic Markers in the Era of Targeted Therapies.
Kang S, Ahn IE. Kang S, et al. Among authors: ahn ie. Acta Haematol. 2024;147(1):33-46. doi: 10.1159/000533704. Epub 2023 Sep 13. Acta Haematol. 2024. PMID: 37703841 Free article. Review.
53 results